Healthcare provider profile · identity verified

Taras Babiak

Family Practice · FORT MYERS, FL · NPI 1013399039

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	518	187
Losartan Potassium	Losartan Potassium	340	118
Amlodipine Besylate	Amlodipine Besylate	237	87
Levothyroxine Sodium	Levothyroxine Sodium	187	58
Lisinopril	Lisinopril	169	60
Gabapentin	Gabapentin	150	55
Metoprolol Succinate	Metoprolol Succinate	129	59
Metformin Hcl	Metformin Hcl	127	50
Rosuvastatin Calcium	Rosuvastatin Calcium	127	48
Prednisone	Prednisone	124	90
Omeprazole	Omeprazole	113	44
Pantoprazole Sodium	Pantoprazole Sodium	112	37
Trazodone Hcl	Trazodone Hcl	112	46
Tamsulosin Hcl	Tamsulosin Hcl	102	43
Albuterol Sulfate Hfa	Albuterol Sulfate	93	44
Ozempic	Semaglutide	89	25
Diclofenac Sodium	Diclofenac Sodium	88	54
Simvastatin	Simvastatin	80	27
Montelukast Sodium	Montelukast Sodium	76	33
Sertraline Hcl	Sertraline Hcl	72	27
Alendronate Sodium	Alendronate Sodium	71	35
Carvedilol	Carvedilol	68	29
Glipizide Er	Glipizide	60	29
Hydralazine Hcl	Hydralazine Hcl	58	30
Glimepiride	Glimepiride	53	20
Duloxetine Hcl	Duloxetine Hcl	52	20
Hydrochlorothiazide	Hydrochlorothiazide	52	20
Metoprolol Tartrate	Metoprolol Tartrate	52	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	46	15
Azithromycin	Azithromycin	43	39
Quetiapine Fumarate	Quetiapine Fumarate	43	15
Symbicort	Budesonide/Formoterol Fumarate	43	19
Fluticasone Propionate	Fluticasone Propionate	42	26
Furosemide	Furosemide	42	19
Eliquis	Apixaban	39	17
Januvia	Sitagliptin Phosphate	38	14
Potassium Chloride	Potassium Chloride	38	13
Breo Ellipta	Fluticasone/Vilanterol	36	suppressed
Ezetimibe	Ezetimibe	36	13
Spironolactone	Spironolactone	35	suppressed
Alprazolam	Alprazolam	34	suppressed
Breyna	Budesonide/Formoterol Fumarate	34	14
Bupropion Xl	Bupropion Hcl	34	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	16
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	29
Pravastatin Sodium	Pravastatin Sodium	33	14
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Xarelto	Rivaroxaban	31	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	12
Paroxetine Hcl	Paroxetine Hcl	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Bupropion Hcl Sr	Bupropion Hcl	28	16
Finasteride	Finasteride	26	suppressed
Ketoconazole	Ketoconazole	26	suppressed
Metformin Hcl Er	Metformin Hcl	26	14
Cephalexin	Cephalexin	25	21
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	19
Nifedipine Er	Nifedipine	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	12
Famotidine	Famotidine	23	11
Meloxicam	Meloxicam	23	suppressed
Atenolol	Atenolol	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	22	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Synthroid	Levothyroxine Sodium	21	suppressed
Torsemide	Torsemide	21	suppressed
Valsartan	Valsartan	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	11
Divalproex Sodium	Divalproex Sodium	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Mirtazapine	Mirtazapine	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Topiramate	Topiramate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Lorazepam	Lorazepam	16	suppressed
Methimazole	Methimazole	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Irbesartan	Irbesartan	15	suppressed
Lactulose	Lactulose	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Digoxin	Digoxin	14	suppressed
Varenicline Tartrate	Varenicline Tartrate	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Clindamycin Hcl	Clindamycin Hcl	13	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Levofloxacin	Levofloxacin	12	suppressed
Mesalamine	Mesalamine	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Amoxicillin	Amoxicillin	11	11
Baclofen	Baclofen	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Glipizide	Glipizide	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error